Immix Biopharma, Inc. announced that it has entered into a securities purchase agreement with a certain accredited investor pursuant to which the company agreed to sell and issue 3,241,076 common shares par value $0.0001 and pre-funded warrants to purchase 1,913,661 shares of common stock. The purchase price per share of common stock is $1.9400 per share and the purchase price for the pre-funded warrants is $1.9399 per pre-funded warrant for the aggregate gross proceeds of $9.999998 million on August 21, 2023. The pre-funded warrants have a per share exercise price of $0.0001, subject to proportional adjustments in the event of stock splits or combinations or similar events.

The pre-funded warrants will not expire until exercised in full. The shares and pre-funded warrants, and the shares issuable upon the exercise of the pre-funded warrants have not been registered under the Securities Act of 1933, as amended.